Clinical trials
Mild Cognitive Impairment Due to Alzheimer's Disease clinical trials
Below are recruiting mild cognitive impairment due to alzheimer's disease clinical trials, each written for real people, not researchers. We’re tracking 112 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07787169RecruitingPhase 1
Study of amyloid-targeting therapies for Alzheimer's disease
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
Anaheim, CaliforniaAges 18–85 - NCT06535308RecruitingPhase 1
Testing a new Alzheimer's drug for moderate disease
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
Seoul, Jongno-guAges 19–45 - NCT07294885Recruiting
Lymphatic surgery for Alzheimer's disease
This study tests a surgical procedure to connect lymph vessels in the neck to veins, which may help clear waste from the brain in people with mild cognitive impairment or mild to moderate Alzheimer's disease. It is for patients who have not improved after at least 3 months of standard care.
ShenyangAges 50–80 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT06052163RecruitingPhase 2
Testing bumetanide for early Alzheimer's disease
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
Stanford, CaliforniaAges 50–85 - NCT02811653Recruiting
Brain movement and memory study in early dementia
This study looks at how “slower movement” and brain changes relate to memory and thinking problems in people with early dementia (and some related conditions). It may help researchers understand what brain differences go with these symptoms, using tests and an MRI scan.
AmiensAges 40–85 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT07758595RecruitingPhase 1
Study of DNL921 for healthy people and people with Alzheimer's disease
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
ManchesterAges 18–75 - NCT07764146RecruitingPhase 1
Study of VY1706 for early Alzheimer's disease
This study tests an experimental treatment called VY1706 for people with early Alzheimer's disease. It aims to see if the treatment is safe and how well it works, and may help slow down the disease.
Maitland, FloridaAges 30–80 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT07497334Recruiting
Improving functional outcomes in cognitively frail older adults
This study tests a program combining cognitive exercises, physical activity, and brain stimulation to improve daily function and thinking in older adults with mild cognitive or physical frailty. The goal is to help you stay independent and improve your quality of life.
Hong KongAges 60–90 - NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT05456503RecruitingPhase 3
PET scan study of tau buildup in memory and brain disorders
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07392723RecruitingPhase 2
Flaxseed nutrition to protect memory in APOE4 adults
This study tests a special flaxseed-based nutrition drink to see if it can slow memory loss in older adults who have the APOE4 gene and mild cognitive impairment (early memory trouble). If you qualify, you'll take the drink daily for a year and have memory tests and brain scans.
New Brunswick, New JerseyAges 60 years+ - NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85 - NCT07109999Recruiting
Biomarker study for Alzheimer's disease
This study uses brain scans or spinal fluid tests to confirm Alzheimer's-related changes. It aims to track the disease over time to better understand and improve care.
Beijing, Beijing MunicipalityAges 40 years+ - NCT03035851Recruiting
Exercise program for older adults at risk of memory decline
This trial tests whether a structured aerobic (heart-pumping) exercise program can improve memory and thinking in older adults who feel memory trouble but have not been diagnosed with dementia. It focuses on people who are “at increased risk” due to common health factors like high blood pressure or diabetes.
Calgary, AlbertaAges 50–80 - NCT06375213Recruiting
Memory and thinking study for all ages
This study looks at how well people think and remember as they age. It includes healthy volunteers, people with mild memory issues, and those with dementia—both early- and late-onset.
Pathum Wan, BangkokAges 35 years+ - NCT06775964RecruitingPhase 1/Phase 2
Stem cell therapy for early Alzheimer's disease
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
Houston, TexasAges 60–80 - NCT06094192Recruiting
Brain stimulation to improve memory in Alzheimer's
This study tests whether a gentle, noninvasive brain stimulation technique called tACS can help improve memory in people with Alzheimer's disease or mild cognitive impairment. It may also include healthy older adults for comparison.
Boston, MassachusettsAges 50–100 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Irvine, CaliforniaAges 50–85
Hear when a new Mild Cognitive Impairment Due to Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild cognitive impairment due to alzheimer's disease?
- Yes. Clin2 currently lists 112 recruiting mild cognitive impairment due to alzheimer's disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild cognitive impairment due to alzheimer's disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild cognitive impairment due to alzheimer's disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.